Thrombomodulin in 1,032 DIC patients with hematologic malignancy.
What is it about?
TM is an ideal treatment for patients with DIC based upon hematologic malignancy.
Why is it important?
Coagulation tests were significantly improved after TM treatment even in subjects whose clinical course of underlying disease was assessed as unchanged or exacerbated.
The following have contributed to this page: Hidesaku Asakura